Maravillas A. S.
- Country
- Spain
- Department
- Oftalmologia
Research Overview
- Evaluation of Satralizumab Efficacy and Safety in Moderate-to-Severe Thyroid Eye Disease: A Phase III Randomized, Double-Masked, Placebo-Controlled Study
- Phase 2b Randomized Double-Mask Placebo-Controlled Trial of Linsitinib in Active Moderate to Severe Thyroid Eye Disease
- A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)
Data & Insights
Has run more than one trial at 4 of 26 partner sites.
Specializations
Ophthalmology & Endocrinology
This investigator specializes in the treatment of Thyroid Eye Disease (TED), with particular focus on moderate to severe cases. Their research explores innovative therapeutic approaches for managing ocular manifestations of thyroid disorders.
- Proptosis Management
- Orbital Disease Treatment
- Thyroid-Related Eye Complications
Their work encompasses evaluation of novel therapeutic agents for orbital inflammation and tissue remodeling.
Therapeutic Development
The investigator conducts research on targeted biological therapies including evaluation of compounds such as satralizumab and linsitinib for ocular conditions.
- Biological Response Modification
- Novel Drug Assessment
- Treatment Response Evaluation
Their research focuses on measuring therapeutic efficacy through objective clinical outcomes in ophthalmology.
Clinical Assessment
Expertise in quantitative measurement of ocular parameters and clinical response evaluation, with specific attention to proptosis assessment and bilateral eye involvement.
- Ocular Measurements
- Disease Activity Monitoring
- Treatment Response Criteria
The investigator employs precise measurement techniques for evaluating therapeutic outcomes in orbital disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.